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Abstract
Introduction: Anterior cruciate ligament (ACL) degeneration is observed in most osteoarthritis (OA)-affected knee
joints. However, the specific spatial and temporal relations of these changes and their association with extracellular
matrix (ECM) degeneration are not well understood. The objective of this study was to characterize the patterns
and relations of aging-related and OA-associated changes in ACL cells and the ECM.
Methods: Human knee joints from 80 donors (age 23 through 94) were obtained at autopsy. ACL degeneration
was assessed histologically by using a quantitative scoring system. Tissue sections were analyzed for cell density,
cell organization, ECM components, ECM-degrading enzymes and markers of differentiation, proliferation, and stem
cells.
Results: Total cell number in normal ACL decreased with aging but increased in degenerated ACL, because of the
formation of perivascular cell aggregates and islands of chondrocyte-like cells. Matrix metalloproteinase (MMP)-1, -3,
and -13 expression was reduced in aging ACL but increased in degenerated ACL, mainly in the chondrocyte-like
cells. Collagen I was expressed throughout normal and degenerated ACL. Collagen II and X were detected only in
the areas with chondroid metaplasia, which also expressed collagen III. Sox9, Runt-related transcription factor 2
(Runx2), and scleraxis expression was increased in the chondrocyte-like cells in degenerated ACL. Alpha-smooth
muscle actin (a-SMA), a marker of myofibroblasts and the progenitor cell marker STRO-1, decreased with aging in
normal ACL. In degenerated ACL, the new cell aggregates were positive for a-SMA and STRO-1.
Conclusions: ACL aging is characterized by reduced cell density and activation. In contrast, ACL degeneration is
associated with cell recruitment or proliferation, including progenitor cells or myofibroblasts. Abnormally
differentiated chondrocyte-like cell aggregates in degenerated ACL produce abnormal ECM and may predispose to
mechanical failure.
Introduction
Anterior cruciate ligament (ACL) degeneration is
observed in most osteoarthritis (OA)-affected knee
joints [1,2]. Our recent observations indicate that histo-
logic changes in ACL, in particular chondroid metapla-
sia, collagen fiber disorganization, and mucoid
degeneration, can occur before the onset of significant
cartilage degeneration in individuals without a history of
knee trauma and at a relatively young age [1]. It is thus
possible that changes in ACL cells and extracellular
matrix (ECM) can be driven by extrinsic factors, for
example, in knees with cartilage damage and inflamma-
tion or, alternatively, intrinsic primary changes in ACL
cells and ECM may lead to ACL mechanical failure.
Limited information is available on changes in ACL
cell density. Cell density in human ACL has been
reported to decrease with age [3], but cell density can
also be increased in ACLs from old OA patients [4].
Changes of ACL cell activation and differentiation status
have also been documented. Chondroid metaplasia is a
feature of degenerated ACL [2,5-7] and may precede
and predispose to structural failure [3,8].
ACLs contain a small subpopulation of fibroblasts
positive for a-smooth muscle actin (a-SMA) [9], as well
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as cells that express certain markers of mesenchymal
progenitor cells, including nucleostemin, SSEA-4,
STRO-1, and Oct-4 [10-12].
The ECM of ACL is composed of collagen types I, II,
III, and V, elastin, and proteoglycans [13,14], with type I
collagen being the main determinant of tensile strength
[15]. Ruptured ACLs express much higher quantities of
mRNA for type I collagen and type III collagen, and
higher quantities of biglycan than normal ACL [16,17].
Collectively, this prior work demonstrated that ACL
aging and degeneration are associated with ACL cell
death, cell proliferation or recruitment, and changes in
ACL differentiation and activation. However, the specific
spatial and temporal relations of these changes and their
association with ECM degeneration are not well under-
stood. The objective of this study was to characterize
cellular and ECM changes in human ACL in aging and
degeneration from a large number of donors across




Human knee joints were processed within 72 hours after
death. In this study, 150 human knee joints were ana-
lyzed, including 41 male and 39 female donors, with a
mean age of 65.5 ± 19.0 years (range, 23 through 94
years). From 70 of 80 donors, we obtained both knees,
whereas from 10 of 80 donors, we obtained only one
knee. Subjects with a history of knee trauma or surgery
were excluded. The causes of death and comorbidities
were similar to those of the general population in the
United States. Human knee joints were obtained at
autopsy with approval of the Scripps Human Subjects
Committee. All study donors provided written informed
consent, according to the Declaration of Helsinki.
Morphologic analysis of articular cartilage
All cartilage surfaces (femoral condyles, trochlea, and
tibial plateaus) were graded macroscopically by using a
modified Outerbridge scoring system and the Interna-
tional Cartilage Repair Society (ICRS) knee map, as
described previously [1].
Macroscopic and histologic analysis of ACL
ACL degeneration was assessed both macroscopically
and histologically, as described [1], by using a modifica-
tion of a previously reported scoring system [2]. Macro-
scopic assessment showed that ACLs in 91 knees were
normal, 46 were abnormal, and 13 were ruptured. The
following categories were examined and scored for each
ligament: (a) inflammation in the ACL substance, (b)
mucoid degeneration, (c) chondroid metaplasia, (d) cys-
tic changes, and (e) orientation of collagen fibers. Each
category was scored from 0 to 3 for the severity of the
degenerative change on both transverse and longitudinal
sections, and a single score was assigned for each ACL.
The highest summed score of ligament degeneration
(total ACL score) was 15 if all five histologic categories
were scored 3 (severe).
ACL degeneration was graded as normal, mild, mod-
erate, and severe after considering the total ACL sub-
stance score. Degeneration of ACL was considered
normal if the total ACL score was 0 to 1, mild if it was
1.5 to 5, moderate if it was 5.5 to 10, and severe if it
was higher than 10. If orientation of collagen fibers,
mucoid degeneration, and/or cystic changes were scored
3, or ACL was completely degraded, and only a few
remnants were detectable macroscopically, it was con-
sidered severe. Donor distribution among the different
ACL grades was as follows: normal (n = 20), mild (n =
92), moderate (n = 22), and severe (n = 16).
To characterize ACL cellular and ECM changes in
aging and degeneration, the donor population was
divided into three groups; normal (<45 years old with
normal ACL and normal cartilage), aging (>60 years old
with mild ACL degeneration and minimal cartilage
degeneration), and degenerated (>60 years old with
moderate to severe ACL degeneration and cartilage
degeneration). ACL sample distribution among the three
different groups was as follows: normal (n = 10 from 7
donors), aging (n = 37 from 23 donors), and degener-
ated (n = 27 from 19 donors). Then 73 ACLs from 47
donors were excluded from the present study because
they did not match the criteria. Three ACLs from two
donors were completely degraded, and ACL samples
were not collected.
Immunohistochemistry
For each group, as defined earlier, 6 normal, 12 aging,
and 10 degenerated ACL samples were used for immu-
nostaining (Table 1). Paraffin-embedded ACL samples
were first deparaffinized in xylene substitute Pro-Par
Clearant (Anatech, Battle Creek, MI, USA) and ethanol
before rehydration in water. After a wash with phos-
phate-buffered saline (PBS), antigen retrieval was per-
formed by incubation with trypsin for 30 minutes at 30°
C before applying type I collagen, type II collagen, type
X collagen, Sox9, Runx2, Scleraxis, and a-SMA anti-
body, or hyaluronidase for 60 minutes at 37°C before
applying type III collagen and aggrecan antibody. Endo-
genous peroxidase was quenched for 10 minutes with
3% H2O2 in methanol. Sections were blocked with 5%
normal rabbit serum for MMP-3 or 10% normal goat
serum for other antibodies for 30 minutes at room tem-
perature. Sections were incubated overnight at 4°C with
primary antibodies against MMP-1 (mab901, R&D
Systems, Minneapolis, MN, USA; 2 μg/ml), MMP-3
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(sc-6839, Santa Cruz Biotechnology, Santa Cruz, CA,
USA; 1:100 dilution), MMP-13 (MAB3321, Chemicon
International, Temecula, CA, USA; 1:1,000 dilution),
Sox9 (AB5535, Chemicon International, Temecula, CA,
USA; 2 μg/ml), Runx2 (sc-10758, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA; 1:50 dilution), Scleraxis
(ab58655, Abcam, Cambridge, MA, USA; 5 μg/ml), Ki-
67 (ab15580, Abcam; 1:200 dilution), a-SMA (ab5694,
Abcam, Cambridge, MA, USA; 1:300 dilution), STRO-1
(mab1038, R&D Systems, Minneapolis, MN, USA; 0.5
μg/ml), collagen I (ab292, Abcam, Cambridge, MA,
USA; 1 μg/ml), collagen II (II-II6B3, Hybridoma Bank,
Iowa City, IA; 2 μg/ml), collagen III (AP07843PU-N,
Acris Antibodies, San Diego, CA, USA; 2 μg/ml), col-
lagen X (ab49945, Abcam, Cambridge, MA, USA;
1:2,000 dilution), and aggrecan (ab3773, Abcam, Cam-
bridge, MA, USA; 1:40 dilution), or negative controls
(normal goat IgG, rabbit IgG, mouse IgG or IgM; 1 μg/ml).
After washing with PBS, sections were incubated with
biotinylated goat anti-mouse IgM (Jackson ImmunoRe-
search Laboratories, West Baltimore, PA, USA; 1:500
dilution) for STRO-1 and collagen type X, biotinylated
goat anti-mouse secondary antibody (Vector Labora-
tories, Burlingame, CA, USA; 1:200 dilution) for MMP-
13, collagen type II and aggrecan, biotinylated rabbit
anti-goat secondary antibody (Vector Laboratories, Bur-
lingame, CA, USA; 1:200 dilution) for MMP-3 or bioti-
nylated goat anti-rabbit secondary antibody (Vector
Laboratories, Burlingame, CA, USA; 1:200 dilution) for
collagen type I, collagen III, Sox9, Runx2, Scleraxis, and
a-SMA for 30 minutes and then incubated with Vectas-
tain ABC-AP kit (AK-5000; Vector Laboratories, Burlin-
game, CA, USA) for 30 minutes at room temperature.
Finally, sections were stained with an alkaline phos-
phatase substrate kit (Vector Laboratories, Burlingame,
CA, USA). The slides were rinsed in tap water and
counterstained with hematoxylin. Slides were washed
and mounted with Prolong Gold Antifade Reagent (Invi-
trogen, Carlsbad, CA, USA).
Quantification and localization of positive cells in human
ACLs
For the quantification of total cell number and positive
cells for each marker in the ACL, at least three different
macroscopic fields (40× magnification) per each sample,
showing the ACL mid-substance, were randomly chosen.
The insertion sites were not included in the analysis.
The total cell number and total number of positive cells
for each marker was counted in each histologic zone by
two different readers, and the percentage of positive
cells was calculated in each field. The interclass correla-
tion between two readers was 0.88. The mean of the
percentage of positive cells by two different readers was
used for the statistical analysis.
Western blotting
Human ACL cells were isolated from the midsubstance
of ACLs and cultured with Dulbecco modified Eagle
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) (Invitrogen, Tastrup, Denmark) and 1%
penicillin/streptomycin (Invitrogen). ACL cells were
used at passage 1 (P1). Western blotting was performed
with the LiCor immunofluorescence detection system
(LI-COR Biosciences, Lincoln, NE, USA). In total, 20 μg
of each cell lysate was separated on 4% to 20% SDS
PAGE gels and transferred to nitrocellulose membranes.
As primary antibodies we used, mouse anti-MMP-1
antibody (mab901; R&D Systems, Minneapolis, MN,
USA; 1 μg/ml), goat anti-MMP-3 antibody (sc-6839,
Santa Cruz Biotechnology, Santa Cruz, CA, USA;
1:1,000 dilution), or rabbit anti-MMP-13 antibody
(ab75606, Abcam, Cambridge, MA, USA; 1:500 dilution)
and rabbit anti-GAPDH (14C10, Cell Signaling, Danvers,
MA; 1:2,000 dilution) or mouse anti-GAPDH antibody
(AM4300, Ambion, Austin, TX, USA; 1:5,000 dilution).
As secondary antibodies, we used goat anti-mouse-
IRDye 800 (LI-COR Biosciences, Lincoln, NE USA; 1/
10,000), donkey anti-goat IRDye 800 (LI-COR Bios-
ciences, Lincoln, NE USA; 1/15,000), or goat anti-rab-
bit-IRDye 800 (LI-COR Biosciences, Lincoln, NE USA;
1/10,000) for MMPs and goat anti-rabbit-IRDye 680 (LI-
COR Biosciences, Lincoln, NE USA; 1/10,000) or goat
anti-mouse-IRDye 680 (LI-COR Biosciences, Lincoln,
NE USA; 1/10,000) for GAPDH. Images were acquired
on the LiCor Odyssey.
Statistical analysis
The results are presented as mean ± SEM (standard
error of the mean). Differences among groups were
determined with one-way analysis of variance (ANOVA)
or Kruskal-Wallis (nonparametric one-way analysis of
variance) procedures with continuous variables, and c2
Table 1 Donor information
Cartilage grade Normal Aging Degenerated
Number 6 ACLs from 4 donors 12 ACLs from 9 donors 10 ACLs from 7 donors
Female/male 3:1 5:4 3:4
Age, mean ± SD years 33.3 ± 11.3 (23-44) 75.0 ± 11.6 (60-94) 78.9 ± 12.3 (60-92)
Body mass index, mean ± SD kg/m2 23.6 ± 6.7 (15.9-29.2) 23.4 ± 5.6 (16.8-33.6) 26.0 ± 8.2 (19.1-43.8)
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procedures with dichotomous variables. Pairwise group
comparisons subsequent to the overall ANOVA tests
were undertaken with the Tukey Student range proce-
dure after parametric ANOVA, or, with the Dwass-
Steel-Critchlow-Fligner (DSCF) procedure, after Krus-
kal-Wallis. The P values of <0.05 were considered statis-
tically significant.
Results
Cell density and cell arrangements
The cell density in histologically normal ACLs from
young donors (<45 years old) with normal (Grade 0)
knee cartilage was 301.4 ± 36.6/mm2, and this was sig-
nificantly reduced to 188.9 ± 13.0/mm2 in ACL from
old donors (>60 years old), with minimal changes in the
articular cartilage (Grade I cartilage) (P = 0.023) (Figure
1A, B, I). In contrast, cell density in degenerated ACLs
from old donors (>60 years old) with degenerated carti-
lage (Grade II to IV) (358.3 ± 51.8/mm2) was as high as
that in the ACL from young donors (Figure 1A, C, D).
In older donors with grade I cartilage, an overall
reduction in cell density was seen across the midsub-
stance of the ACL (Figure 1B). The ACL from older
donors with cartilage degeneration (Grades II through
IV) showed also a reduction in normally arranged cells.
However, hypercellular areas were observed around
blood vessels, and these cells had a fibroblast-like shape
(Figure 1C). A separate type of new cell aggregates
occurred independent of blood vessels and included
cells with a chondrocyte-like morphology (Figure 1D).
These cells were not aligned with collagen fibers, and
cell arrangements represented islands with large num-
bers of cells interspersed within the hypocellular areas.
Fibroblast-like cell aggregates were present in 12 (44.4%)
of 27 degenerated ACL groups, and this was signifi-
cantly more common than normal (0 of 8; none) and
aging group (5 (13.5%) of 37) (P = 0.004 with c2 analy-
sis). Chondrocyte-like cell aggregates were present in 14
(51.9%) of 27 of the degenerated ACL group, and this
was significantly more common than in the normal
(none of eight) and aging group (five (13.5%) of 37 (P =
0.0005 by c2 analysis). Nine (33.3%) of 27 degenerated
ACLs contained both fibroblast-like cell aggregates and
chondrocyte-like cell aggregates. Dense cell clusters, as
typically seen in OA articular cartilage, were observed in
4 of 150 ACLs (2.7%), which were associated with dis-
ruption of collagen fibers and/or mucoid degeneration
from knees with cartilage degeneration.
Thus, a general reduction in ACL cellularity occurs in
aging. However, in degenerated ACLs, two distinct types
of localized high cell-density aggregates are noted. In
the following immunohistochemical studies, fibroblast-
like cell aggregates and chondrocyte-like cell aggregates
were examined separately.
Cell proliferation
Ki-67 is a cell-proliferation marker [5]. In normal ACLs,
27.2% ± 4.1% of ligament cells were Ki-67 positive. The
number of Ki-67-positive cells decreased with aging
(3.9% ± 1.2%; P < 0.0001) (Figure 1E, F), whereas in
degenerated ACLs, the number of Ki-67-positive cells
increased (59.0% ± 3.6%; P < 0.0001). Of fibroblast-like
cells, 45.1% ± 4.5% were Ki-67 positive, whereas 72.9% ±
3.3% of chondrocyte-like cells were Ki-67 positive
(Figure 1G, H).
Cell differentiation
Sox9 is a transcription factor known to be involved in
the modulation of the chondrocyte phenotype [18]. In
normal ACLs, 13.5% of cells were Sox9 positive, and
Sox9-positive cells decreased with aging (2.0% ± 0.7%; P
< 0.0001). In the degenerated ACLs, 60.1% of chondro-
cyte-like cells were Sox9 positive; however, only 8.4% of
fibroblast-like cells were Sox9 positive (P < 0.0001)
(Figure 2A through D).
Runx2 is a transcription factor that regulates chondro-
cyte hypertrophy [18]. In normal and aging ACLs, a few
Runx2-positive cells were found. In the degenerated
ACLs, 8.5% of fibroblast-like cells were Runx2 positive,
whereas 62.4% of chondrocyte-like cells were Runx2
positive (P < 0.0001) (Figure 2E through H).
Transcription factor scleraxis (Scx) is a highly specific
marker of the tendon/ligament lineage that regulates
fibroblast differentiation and ECM synthesis during
embryonic tendon/ligament development [19,20]. In
normal ACLs, 8.0% of cells were Scx positive, and the
percentage of Scx-positive cells in the aging group was
2.0% ± 0.9% (P = 0.09) (Figure 2I, J). In the degenerated
ACLs, 50.1% of chondrocyte-like cells were Scx positive;
however, only 3.4% of fibroblast-like cells were positive
(P < 0.0001) (Figure 2K, L). These results indicate
abnormal expression of differentiation markers in chon-
drocyte-like aggregates in the degenerated ACL.
Progenitor cell markers
a-Smooth muscle actin (a-SMA) is a marker of myofi-
broblasts and also immature or stem cells [21]. a-SMA-
positive cells were observed in dense collagenous tissue,
perivascular area, and lining cells in the synovial sheath.
In normal ACLs, 43.1% of ligament cells were positive
(Figure 3A). The number of positive cells decreased
with aging (10.3% ± 3.4%; P < 0.0001) (Figure 3B). But
the average percentage of a-SMA positive cells in
degenerated ACLs (55.9 ± 3.6%) was higher than that in
the aging group (10.3% ± 3.4%; P < 0.0001). 72.4% of
chondrocyte-like cells and 39.4% of fibroblast-like cell
aggregates were a-SMA positive (Figure 3C, D).
STRO-1 is a marker of mesenchymal stem cells [22].
STRO-1-positive cells were observed in dense collagenous
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tissue, perivascular areas, and lining cells in the synovial
sheath. In normal ACLs, 49.2% ± 3.5% of ligament cells
were STRO-1 positive (Figure 3E). The number of posi-
tive cells decreased with aging (25.0% ± 3.7%; P < 0.0001)
(Figure 3F), but the average percentage of STRO-1-posi-
tive cells in ACLs from the degenerated group (59.0% ±
3.0%) was higher than that in the aging group (25.0% ±
3.7%; P < 0.0001); 67.6% ± 3.1% of chondrocyte-like cells
were positive, whereas 50.5% ± 4.2% of fibroblast-like
cells were STRO-1 positive (Figure 3G, H). The expres-
sion patterns of a-SMA and STRO-1 in normal and
degenerated ACLs were similar (Figure 3I).
Figure 1 Cell organization, cell density, and Ki-67 expression in ACL. (A-D) H&E staining; (E-H) Ki-67 (original magnification ×40). Sections
of ACL representing (A, E) normal cell distribution in ACL from young normal knee; (B, F) hypocellular ACL from aging knee; (C, G) fibroblast-
like cell aggregates in degenerated ACL; (D, H) chondrocyte-like cell aggregates in degenerated ACL. Black arrows, Ki-67-positive cells; white
arrows, Ki-67-negative cells. The graph (I) represents the total cell density in each ACL group. The graph (J) represents the percentage of
Ki-67-positive cells. The results are presented as mean ± SEM. *P < 0.05; **P < 0.01.
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MMP-1, MMP-3, and MMP-13 expression
The average percentage of MMP-1-positive cells in the
aging group (23.0% ± 2.3%) was significantly lower than
in the normal and degenerated groups (43.4% ± 2.5% and
51.5% ± 5.1; P = 0.0003; P = 0.015, respectively) (Figure
4A, B, M). The average percentage of MMP-1-positive
cells in ACLs from the degenerated group, however, was
as high as that in the young group. In regard to the two
different patterns of cell aggregates in the degenerated
ACLs, only 20.9% of the fibroblast-like cells near the
Figure 2 Sox9, Runx2, and Scleraxis expression. (A-D) Sox9; (E-H) Runx2; (I-L) Scleraxis. (A,E,I) ACL from normal knee; (B,F,J) ACL from aging
knee; (C,G,K) fibroblast-like cell aggregates in the degenerated ACL. (D,H,L) Chondrocyte-like cell aggregates in the degenerated ACL. Black
arrows, positive cells; white arrows, negative cells. (Original magnification ×40). The graph (M) represents the percentage (mean ± SEM) of Sox9-,
Runx2-, and Scleraxis-positive cells. **P < 0.01.
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blood vessels were MMP-1 positive, whereas 76.9% of
chondrocyte-like cells were MMP-1 positive (P < 0.0001)
(Figure 4C, D, M).
The average percentage of MMP-3-positive cells in the
aging group (8.2% ± 1.6%) was significantly lower than
in the normal and degenerated group (39.1% ± 4.5% and
36.3% ± 4.7; P = 0.0002; P = 0.0009, respectively) (Figure
4E, F, M). But the average percentage of MMP-3-posi-
tive cells in ACLs from the degenerated group was as
high as in the young group. In regard to the two differ-
ent patterns of cell aggregates in the degenerated ACLs,
only 15.4% of the fibroblast-like cells near the blood
vessels were MMP-3 positive, whereas 65.4% of chon-
drocyte-like cells were MMP-3 positive (P < 0.0001)
(Figure 4G, H, M).
The average percentage of MMP-13-positive cells in
normal ACL (39.8% ± 2.8%) also decreased with aging
(21.5% ± 2.5%; P = 0.0002) (Figure 4I, J, M). In the
degenerated ACL, 21.2% of the fibroblast-like cells near
the blood vessels were MMP-13 positive, whereas 76.4%
of chondrocyte-like cells were MMP-13 positive (P <
0.0001) (Figure 4K, L, M). We used Western blotting to
quantify MMP-1, -3, and -13. The expression of MMP-
1, -3, and -13 decreased with aging. However, the
Figure 3 a-SMA and STRO-1 expression. (A-D) a-SMA; (E-H) STRO-1. (A,E) ACL from young normal knee; (B,F) ACL from aging knee; (C,G)
fibroblast-like cell aggregates in the degenerated ACL; (D,H) chondrocyte-like cell aggregates in the degenerated ACL. Black arrows, positive
cells; white arrows, negative cells. (Original magnification ×40). (I) The graph represents the percentage (mean ± SEM) of a-SMA- and STRO-1-
positive cells. **P < 0.01.
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Figure 4 MMP-1, MMP-3, and MMP-13 expression. (A-D) MMP-1; (E-H) MMP-3; (I-L) MMP-13 (A,E,I) ACL from young normal knee; (B,F,J)
ACL from aging knee; (C,G,K) fibroblast-like cell aggregates in the degenerated ACL; (D,H,L) chondrocyte-like cell aggregates in the
degenerated ACL. (Original magnification ×40). The graph (M) represents the percentage (mean ± SEM) of MMP-1-, MMP-3-, and MMP-13-
positive cells in each group. **P < 0.01. (N) Western blotting for MMP-1, MMP-3, and MMP-13 (n = 3 for each category).
Hasegawa et al. Arthritis Research & Therapy 2013, 15:R29
http://arthritis-research.com/content/15/1/R29
Page 8 of 12
expression of MMP-1, -3, and -13 in the degenerated
group was as high as in the young-normal group (Figure
4N).
Thus, constitutive MMPs expression declines with
aging, and a marked upregulation occurs in degenerated
ACLs in the joints with cartilage degeneration.
Extracellular matrix changes
To assess ECM changes, we performed immunohisto-
chemistry for collagens type I, II, III, and X and aggre-
can. In the normal and aging ACL, most collagen
bundles were type I collagen positive (Figure 5A, B). In
the degenerated ACL, ECM around fibroblast-like cell
aggregates were type I collagen positive; however, stain-
ing intensity of ECM around chondrocyte-like cell
aggregates was lower (Figure 5C, D).
In the normal ACL, type II collagen is located in
fibrocartilaginous zones, situated where the ligament
inserts into bone [14]. Figure 5E and 5F shows histolo-
gic sections from the ACL midsubstance, and these
regions were negative. In the degenerated ACL with
chondroid metaplasia, we observed type II collagen
around the chondrocyte-like cells in the ACL midsub-
stance but not the fibroblast-like cells (Figure 5E
through H).
In the normal ACL, type III collagen is located within
the loose connective tissue that divides the collagen
fibrils of the ligament into small bundles but not dense
collagenous tissues. In the degenerated ACL, we
observed type III collagen in the ACL midsubstance
with chondrocyte-like cell aggregates as well as the
loose connective tissues (Figure 5I through L). Type X
Figure 5 Collagen types I, II, and III. (A-D) Collagen type I, (E-H) collagen type II, (I-L) collagen type III (A, E, I) ACL from young normal knee;
(B, F, J) ACL from aging knee; (C, G, K) fibroblast-like cell aggregates in the degenerated ACL; (D, H, L) chondrocyte-like cell aggregates in the
degenerated ACL. Most collagen bundles were type I collagen positive (A-D), however, staining intensity of the ECM around chondrocyte-like
cell aggregates was lower (black arrows). Type II collagen-positive area is observed around chondrocyte-like cell aggregates (white arrows). In the
normal ACL, type III collagen is located within the loose connective tissue (black arrowheads) that divides the collagen fibrils of the ligament
into small bundles but not dense collagenous tissues. In the degenerated ACL, type III collagen (white arrowheads). (Original magnification ×40).
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collagen is a hypertrophic chondrocyte marker. We
observed type X collagen around the chondrocyte-like
cells but not the fibroblast-like cells (Figure 6A through
D). Aggrecan is expressed predominantly in fibrocartila-
ginous zone of normal tendon and ligament [23]. Aggre-
can was not observed within the ligament midsubstance.
But in the ACL with chondroid metaplasia, aggrecan
was also observed around the chondrocyte-like cells
within the ligament midsubstance. In degenerated ACL,
chondrocyte-like cells were aggrecan positive, whereas
fibroblast-like cells were negative (Figure 6E through H).
Discussion
ACL rupture represents a risk factor for cartilage degra-
dation and OA development [24,25]. Aging-related
degenerative changes in the ACL may also contribute to
OA onset and progression, but mechanisms of ACL
aging and degradation are not well characterized [26,27].
The present study used a large collection of human knee
joints to document changes in ACL cells and extracellu-
lar matrix and correlated these changes with overall
ACL histopathology grade and macroscopic assessment
of the articular surfaces.
To profile normal ACL aging, we analyzed ACLs from
a subset of older individuals with macroscopically nor-
mal ACLs and minimal degeneration of articular carti-
lage. The ACLs in these knees differed from normal
ACLs from younger donors by an overall reduction in
tissue cellularity and reduced cell activation and
proliferation.
Degenerated ACLs showed marked changes in cell
organization. As compared with normal aging ACLs, a
further reduction occurred in the cells that are normally
distributed along collagen bundles. However, total cell
numbers were increased, because of the presence of two
types of new cell aggregates. The first was perivascular
accumulation of cells. The second was cell aggregates
that were not associated with blood vessels but located
in areas with degraded or remodeled ECM. The expres-
sion of the proliferation marker Ki-67 was lower in nor-
mal aging ACLs and increased in both fibroblast- and
chondrocyte-like cell aggregates in degenerated ACLs.
This suggests that constitutive cell turnover declines
with aging and that cell proliferation accounts at least in
part for the formation of the cell aggregates in degener-
ated ACLs.
We used several differentiation (Sox9, Scx, and Runx2)
and progenitor cell (a-SMA, STRO-1) markers the better
to characterize ACL cell populations. Sox9 is a transcrip-
tion factor involved in the modulation of the chondrocyte
phenotype [28-30]. The percentage of Sox9-positive cells
increased in the degenerated ACLs compared with normal
and aging ACLs. In the degenerated ACLs, 60.1% of chon-
drocyte-like cells were Sox9 positive, whereas only 8.4% of
fibroblast-like cells were Sox9 positive. These results sug-
gest that a subpopulation of ACL cells differentiate into
Figure 6 Collagen type X and aggrecan. (A-D) Collagen type X; (E-H) aggrecan; (A,E) ACL from young normal knee; (B,F) ACL from aging
knee; (C,G) fibroblast-like cell aggregates in the degenerated ACL; (D,H) chondrocyte-like cell aggregates in the degenerated ACL. Type X
collagen-positive area is observed around chondrocyte-like cell aggregates (black arrows), and aggrecan was observed around chondrocyte-like
cell aggregates in the ACL midsubstance (white arrows). (Original magnification ×40).
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the chondrocyte-like phenotype in OA-affected knee
joints. Transcription factor Scx is a distinct marker for
tendon and ligament progenitors and for differentiated
cells [20,31]. Scx promotes the expression of tenomodulin,
a differentiation marker of tenocytes [32]. Normal human
ACLs contain only a few Scx-positive cells. In degenerated
ACLs, however, 50.1% of cells in the chondrocyte-like cell
aggregates were positive for Scx, whereas only 3.4% of
cells in the fibroblast-like cell aggregates were positive.
Runx2, a regulator of chondrocyte hypertrophy, also was
most strongly upregulated in the chondrocyte-like cell
aggregates. Collectively, these results on differentiation
markers suggest that chondrocyte-like aggregates contain
abnormally differentiated cells that express both hyper-
trophic chondrocyte and immature tendon cell markers.
We used several markers that characterize progenitor
cells and fibroblast subpopulations. Small populations of
fibroblast-like cells are present in the circulation. In the
adult, these cells arise mainly in the bone marrow [33,34]
and resemble mesenchymal stem cells [35,36]. A second
population also arises from adult bone and circulates as a
monocyte-like cell that continues to express hematopoie-
tic antigens such as CD34 and CD45. These cells also
home to wound sites where they assume a fibroblast-like
phenotype and produce collagens, containing vimentin
cytoplasmic filaments. These cells have been termed
fibrocytes [37]. Myofibroblasts are a subset of fibroblasts
defined by the presence of organized a-SMA cytoplasmic
filaments [38,39]. These cells have the potential to con-
tract ECM, and they are enriched in sites of tissue injury
and wound healing [40]. In degenerated ACLs, we found
an increased number of fibroblast-like cells near the
blood vessels. Many of these cells were STRO-1 positive
and CD45 positive (data not shown). This result suggests
that ACL degeneration is associated with recruitment of
bone marrow-derived fibrocytes. In addition, chondro-
cyte-like cell aggregates also expressed STRO-1 and a-
SMA. As these cells are more strongly positive for Ki-67
and located at a greater distance from blood vessels, they
may originate from resident progenitors, which are pre-
sent in normal ACLs [10,12]
Thus, ACL degeneration is associated with cell
recruitment or proliferation, including progenitor cells
or myofibroblasts. Chondrocyte-like cells in the degener-
ated ACLs might be abnormally differentiated from resi-
dent progenitor cells and locally proliferated, whereas
fibroblast-like cells in the perivascular area might be
bone marrow-derived cells.
To characterize ECM remodeling, we analyzed MMP-
1, MMP-3, MMP-13, and several ECM molecules. The
average percentage of MMP-1-positive cells, MMP-3-
positive cells, and MMP-13 positive cells in ACLs from
normal knees decreased with aging, but increased in
degenerated ACLs from knees with severe cartilage
degeneration. Cells expressing MMP-1, MMP-3, and
MMP-13 in degenerated ACLs were predominantly cell
aggregates of chondrocyte-like cells but not fibroblast-
like cells. These results suggest that the decrease of
MMP-1-, MMP-3-, and MMP-13-positive cells and total
cell number density with aging may reflect a reduced
capacity to remodel and maintain the tissue, whereas
increased MMP-1-positive cells, MMP-3-positive cells,
and MMP-13-positive cells in ACLs from knees with
severe cartilage degeneration may be caused by phenoty-
pic changes and contribute to degeneration.
We found reduced type I collagen around the chon-
drocyte-like cells in degenerated ACLs. Interestingly,
type II, III, and X collagen and aggrecan were increased
around these cells in degenerated ACLs. These results
suggest that chondroid metaplasia contributes to the
abnormal ECM production, which can lead to biome-
chanical failure [5,41].
Conclusions
The relatively large sample set in this study showed the
cellular changes and associated ECM changes. ACL
aging is characterized by reduced cell density and activa-
tion. In contrast, ACL degeneration is associated with
cell recruitment or proliferation, including progenitor
cells or myofibroblasts. This cellular response to ACL
tissue damage illustrates the regenerative capacity of
ACL cells. Conversely, the chondrocyte-like phenotype
produces abnormal ECM and may predispose to
mechanical failure.
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